Medication management of irritable bowel syndrome

Digestion

Volumn 89, Issue 4, 2014, Pages 253-267

  Trinkley, Katy E ^a   Nahata, Milap C ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Constipation; Diarrhea; Functional gastrointestinal disorders; Irritable bowel syndrome; Medications; Therapeutics

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; DICYCLOVERINE; DOXEPIN; FLUOXETINE; GABAPENTIN; HYOSCYAMINE; IMIPRAMINE; ISPAGULA; KETOTIFEN; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; OCTREOTIDE; PAROXETINE; PEPPERMINT OIL; PREGABALIN; RIFAXIMIN; TRIMIPRAMINE; ASIMADOLINE; AST 120; CLONIDINE; ELUXADOLINE; EMICERFONT; IBODUTANT; MU OPIATE RECEPTOR AGONIST; SCOPOLAMINE; TOFISOPAM; UNINDEXED DRUG; NEW DRUG;

DIET SUPPLEMENTATION; DRUG DOSE REGIMEN; EVIDENCE BASED PRACTICE; HUMAN; IRRITABLE COLON; MEDICATION THERAPY MANAGEMENT; PRIORITY JOURNAL; REVIEW; ARTICLE; BRAN; DRUG EFFICACY; EVIDENCE BASED MEDICINE; PATIENT CARE; TREATMENT DURATION; IRRITABLE BOWEL SYNDROME;

DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 84927582757     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000362405     Document Type: Review

References (63)

1. Hungin APS, Chang GR, Locke GR, Dennis EH, Bargout V: Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact. Alimentary Pharmacol Ther 2005; 21: 1365-1375
2. Brandt LJ, Bjorkman D, Fennerty B, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97:S7-S26
3. Brandt LJ, Chey WD, Foxx-Orenstein AE, Quigley EMM, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Moayyedi P: An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104:S8-S35
4. Lubiprostone. Package Insert. Takeda Pharmaceuticals America, Inc., April 2013. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/ 021908s011lbl.pdf. Accessed June 4, 2014
5. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R: Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-696
6. Johnston JM, Lurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ: Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterol 2010; 139: 1877-1886
7. Quigley EMM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM: Randomized clinical trials: Linaclotide phase 3 studies in IBS-C-A prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37: 49-61
8. Rao SR, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneider HA, Kurtz CB, Johnston JM: A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-1724
9. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneider HA, Johnston JM: Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-1712
10. Lembo A, Zakko SF, Ferreira NL, Ringel Y, Bortey E, Courtney K, Corsi E, Forbes WP, Pimentel M: Rifaximin for the treatment of diarrhea associated irritable bowel syndrome: Short-Term treatment leading to long-Term sustained response (abstract T1390). Gastroenterology 2008; 134(suppl 1):A545
11. Rifaximin. Package Insert. Salix Pharmaceuticals, Inc., March 2013. Available at: Http:// www.accessdata.fda.gov/drugsatfda-docs/label/2014/ 021361s013lbl.pdf. Accessed June 4, 2014
12. Food and Drug Administration. Xifaxan (rifaximin) tablets, 550 μg NDA 21-361: Briefing document for gastrointestinal drugs advisory committee meeting 16 November 2011. Available at http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/ drugs/ gastrointestinaldrugsadvisorycommittee/ ucm279646.pdf. Accessed September 27, 2013
13. Jalihal A, Kurian G: Ispaghula therapy in irritable bowel syndrome: Improvement in overall well-being is related to reduction in bowel dissatisfaction. J Gastroenterol Hepatol 1990; 5: 507-513
14. Bijkerk CJ, De Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW: Soluble or insoluble fibre in irritable bowel syndrome in primary care?. Randomised placebo controlled trial. BMJ 2009; 339:b3154
15. Prior A, Whorwell P: Double blind study of ispaghula in irritable bowel syndrome. Gut 1987; 28: 1510-1513
16. Arthurs Y, Fielding JF: Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. Irish Med J 1983; 76: 253
17. Ritchie JA, Truelove SC: Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1979;i:376-378
18. Longstreth GF, Fox DD, Youkeles L, Forsythe AB, Wolochow DA: Psyllium therapy in the irritable bowel syndrome. Ann Intern Med 1981; 95: 53-56
19. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK: Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial. J Gastroenterol 1997; 2: 765-768
20. Alam MS, Roy PK, Miah AR, Mollick SH, Han MR, Mahmud MC, Khatun S: Efficacy of peppermint oil in diarrhea predominant IBS-A double-blind randomized placebo-controlled study. Mymensingh Med 2013; 22: 27-30
21. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L: Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: A prospective double-blind placebo controlled randomized trial. Dig Liver Dis 2007; 39: 530-536
22. Page JG, Dirnberger GM: Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981; 3: 153-156
23. Cann PA, Read NW, Holdsworth CD, Barends D: Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-247
24. Efskind PS, Bernklev T, Vatn MH: A doubleblind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-468
25. Lavo B, Stenstam M, Nielsen AL: Loperamide in treatment of irritable bowel syndrome-A double-blind placebo-controlled study. Scand J Gastroenterol 1987; 130:S77-S80
26. Loperamide. Package Insert. Janssen Pharmaceutica Inc., July 1998. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/ 017694s050lbl.pdf. Accessed June 4, 2014
27. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J: A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095-1103
28. Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R: The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A doubleblind randomized-controlled study. Aliment Pharmacol Ther 2005; 22: 381-385
29. Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA: A doubleblind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 1990; 50: 78-86
30. Vahedi H, Merat S, Momtahen S, Kazzazi S, Ghaffari N, Olfati G, Malekzadeh R: Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 678-684
31. Rajagopalan M, Kurian G, John J: Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998; 13: 738-741
32. Bahar RJ, Collins BS, Steinmetz B, Ament ME: Double-blind, placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008; 152: 685-689
33. Myren J, Groth H, Larssen SE, Larsen S: The effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1982; 17: 871-875
34. Myren J, Lovland B, Larssen S-E, Larsen S: A double-blind study of the effect of trimipramine in patients with irritable bowel syndrome. Scand J Gastroenterol 1984; 19: 835-843
35. Greenbaum DS, Mayle JE, Vanegeren LE, Jerome JA, Mayor JW, Greenbaum RB, Matson RW, Stein GE, Dean HA, Halvorsen NA: Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32: 257-266
36. Vij JG, Jiloha RG, Kumar N: Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Ind J Psychiatry 1991; 33, 243-246
37. Kooker TK, Braak B, Koopman KE, Welting O, Wouters MM, Van Der Heide S, Schemann M, Bischoff SC, Van Den Wijngaard RM, Boeckxstaens GE: The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-1221
38. Lee KJ, Kim JH, Cho SW: Gabapentin reduces rectal mechanosensitivity and increases compliance in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 981-988
39. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD: Effect of a second-generation a 2 d ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56: 1218-1225
40. Klooker TK, Kuiken SD, Lei A, Boeckxstaens GE: Effect of long-Term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 605-615
41. Octreotide. Package Insert. Novartis Pharmaceuticals Corporation March 2012. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 019667s061lbl.pdf. Accessed June 4, 2014
42. Camilleri M, Kim DY, McKinzie S, Kim HJ, Thomforde GM, Burton DD, Low PA, Zinsmeister AR: A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1: 111-121
43. Clinical trials.gov: Find Studies. Available at clinicaltrials.gov. Accessed November 19, 2013
44. Lazard Capital Markets Annual Healthcare Conference. Furiex Pharmaceuticals. Available at http://files.shareholder.com/downloads/ABEA- 4H9PM3/0x0x550458/a546b8d0-d614-4136-9514-3c960c74649f/ Lazard%20Capital%20Markets%20Annual%20Healthcare%20Conference%20Presentation. Accessed November 11, 2013
45. Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H: Clinical trial: The glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: A randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009; 29: 198-206
46. Tack JF, Miner PB, Fischer L, Harris MS: Randomised clinical trial: The safety and efficacy of AST-120 in non-constipating irritable bowel syndrome-A double-blind, placebocontrolled study. Aliment Pharmacol Ther 2011; 43: 868-877
47. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D: Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 239-249
48. Whitehead WE, Palsson OS, Gangarosa L, Turner M, Tucker J: Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 944-e400
49. Pimentel M, Sandy P, Mirocha J, Kane SV, Kong Y: The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006; 145: 557-563
50. Pimental M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32
51. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R: The effect of entericcoated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010; 55: 1385-1390
52. Hovdenak N: Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol 1987; 130:S81-S84
53. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M: Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008; 53: 108-115
54. Heefner JD, Wilder RM, Wilson ID: Irritable colon and depression. Psychosomatics 1978; 19: 540-547
55. Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, Jin C, Grimes B, Pepin CJ: Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010; 8: 42-48
56. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE: The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-228
57. Forte LR Jr: Uroguanylin and guanylin peptides: Pharmacology and experimental therapeutics. Pharmacol Ther 2004; 104: 137-162
58. Eutamene H, Bradesi S, Larauce M, Theodorou V, Beaufrand C, Ohning G, Fiormonti J, Cohen M, Bryant AP, Kurtz C, Currie MG, Mayer EA, Bueno L: Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22: 312-e84
59. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J: Restoration of barrier function in injured intestinal mucosa. Physiol Rev 2007; 87: 545-564
60. Hills JM, Aaronson PI: The mechanism of action of peppermint oil on gastrointestinal smooth muscle. Gastroenterology 1991; 101: 55-65
61. Sohn W, Yee OY, Kwon JG, Park KS, Lim YJ, Kim TH, Jung SW, Kim JI: Tianeptine vs. amitriptyline for the treatment of irritable bowel syndrome with diarrhea: A multicenter, openlabel, non-inferiority, randomized controlled study. Neurogastroenterol Motil 2012; 24: 860-e398
62. Medi-Span. Medi-Span Average WAC Pricing File. Available at http://www.medispan. com/average-wac-pricing-file/. Accessed November 16, 2013
63. Bubenik GA: Gastrointestinal melatonin: Localization, function, and clinical relevance. Dig Dis Sci 2002; 47: 2336-2348.